Alterity Therapeutics Limited, a development stage enterprise, has announced a new securities issue on July 18, 2024. The company, listed under the ASX issuer code ATH, plans to issue a total of 75,220,800 ordinary fully paid shares at an issue price of AUD 0.00540 per share. The purpose of the issue is to support further research and development activities and provide ongoing working capital. The issue will proceed without the need for security holder approval, utilizing the company's additional 10% placement capacity under listing rule 7.1A, chosen for its cost-effectiveness and timing benefits over other methods such as a pro rata issue or a security purchase plan. The newly issued securities will rank equally with existing securities and are not subject to any restrictions or voluntary escrow.

Alterity Therapeutics Limited, a development stage enterprise, has announced a new securities issue on July 18, 2024. The company, listed under the ASX issuer code ATH, plans to issue a total of 75,220,800 ordinary fully paid shares at an issue price of AUD 0.00540 per share. The purpose of the issue is to support further research and development activities and provide ongoing working capital. The issue will proceed without the need for security holder approval, utilizing the company's additional 10% placement capacity under listing rule 7.1A, chosen for its cost-effectiveness and timing benefits over other methods such as a pro rata issue or a security purchase plan. The newly issued securities will rank equally with existing securities and are not subject to any restrictions or voluntary escrow.